Hou Xin-pu, Wang Li, Wang Xiang-tao, Li Sha
Department of Pharmaceutics, School of Pharmacy, Peking University, Beijing 100083, China.
Yao Xue Xue Bao. 2003 Feb;38(2):143-6.
To target for hepatocytic cell, liposomes was modified by special ligand.
Sterically stabilized liposomes (SSL) was conjugated with asialofeticin (AF), the ligand of asialoglycoprotein receptor (ASGP-R) of hepatocyte. ASGP-R-BLM is the ASGP-R reconstructed on bilayer lipid membrane (BLM). The recognition reaction between AF-SSL and ASGP-R-BLM can be monitored by the varieties of membrane electrical parameters. The targetability of AF-SSL mediated to hepatocyte was detected by radioisotopic labeled in vitro and in vivo. The therapeutic effect of antihepatocarcinoma was observed also.
The lifetime of ASGP-R-BLM decreased with the added amount of AF-SSL. It was demonstrated that there was recognition reaction between AF-SSL and ASGP-R-BLM. The combination of AF-SSL with hepatocyte was significantly higher than that of SSL without AF-modified in vitro and in vivo. The survival time of rat for AF-SSL carriered ADM (adriamycin) group was much longer and the toxicities on heart, kidney and lung were lower than those SSL carried ADM group.
It is possible to actively target the cell with specific receptor by ligand modified liposomes. The result prvide scientific basis of hepatocyte targeted liposomes.
为了靶向肝细胞,用特殊配体修饰脂质体。
将空间稳定脂质体(SSL)与去唾液酸胎球蛋白(AF)偶联,AF是肝细胞去唾液酸糖蛋白受体(ASGP-R)的配体。ASGP-R-BLM是在双层脂质膜(BLM)上重建的ASGP-R。AF-SSL与ASGP-R-BLM之间的识别反应可通过膜电参数的变化来监测。通过体外和体内放射性同位素标记检测AF-SSL介导对肝细胞的靶向性。还观察了抗肝癌的治疗效果。
ASGP-R-BLM的寿命随AF-SSL添加量的增加而降低。证明AF-SSL与ASGP-R-BLM之间存在识别反应。在体外和体内,AF-SSL与肝细胞的结合显著高于未用AF修饰的SSL。携带AF-SSL阿霉素(ADM)组大鼠的存活时间长得多,对心脏、肾脏和肺的毒性低于携带SSL阿霉素组。
用配体修饰的脂质体有可能主动靶向具有特异性受体的细胞。该结果为肝细胞靶向脂质体提供了科学依据。